abstract |
The present invention provides a modified human tumor necrosis factor receptor-1 polypeptide or fragment thereof that binds to tumor necrosis factor in vivo or ex vivo. Modified human tumor necrosis factor receptor-1 polypeptides or fragments thereof of the present invention exhibit improved resistance to proteolytic enzymes present in vivo, thus resulting in improved bioavailability and uptake. |